|Trade names||Zinnat, Ceftin, Ceftum|
|Other names||Cefuroxime 1-acetoxyethyl ester|
|Oral, IV, IM|
|Metabolism||Cefuroxime is not metabolized and excreted as it is in urine, Axetil is metabolized to acetaldehyde and acetic acid.|
|CompTox Dashboard (EPA)|
|Chemical and physical data|
|Molar mass||510.47 g·mol−1|
|3D model (JSmol)|
It was patented in 1976 and approved for medical use in 1987.
Second generation cephalosporins are more effective in treating Gram-negative bacilli compared to first generation cephalosporins, which have a greater coverage for Gram-positive cocci. Also, it has been reported that cefuroxime is resistant to hydrolysis by β-lactamases produced by Gram-negative bacteria.
- Upper respiratory tract infections.
- Lower respiratory tract infections.
- Urinary tract infections.
- Skin and soft tissue infections.
- Early Lyme disease.
Gram-positive aerobic microorganisms
- Staphylococcus aureus (Methicillin-sensitive only)
- Staphylococcus epidermis
- Streptococcus pneumoniae (Penicillin-sensitive only)
Gram-negative aerobic microorganisms
- Haemophilus influenzae
- Moraxella catarrhalis
- Neisseria gonorrhoeae
- Escherichia coli
- Proteus mirabilis
- Klebsiella pneumoniae (variable activity)
Mechanism of action
Cefuroxime axetil is a second generation cephalosporin that, like penicillins antibiotics, contains a β-lactam ring structure. Cephalosporins works as a bactericidal antibiotic; that by binding to penicillin-binding proteins (PBPs), inhibit the last step of the bacterial cell wall synthesis. Once the β-lactam ring binds to PBPs, cross-linking between peptidoglycan units is inhibited.
Absorption: Once consumed, cefuroxime axetil is converted to the active compound cefuroxime by esterases of mucosal cells in the gastrointestinal tract. Cefuroxime is then released for systematic circulation. If cefuroxime axetil is given with food, absorption values can increase by 52% compared to fasting patients.
Distribution: It has been reported that after cefuroxime axetil administration, it can be found in tonsil tissue, sinus tissue, bronchial tissue and middle ear effusion.
Elimination: After cefuroxime production, the body is unable to metabolize the drug, and is eliminated unchanged in the urine.
- Walter Sneader (2005-06-23). Drug Discovery: A History. John Wiley, Chichester, UK. ISBN 0-471-89979-8.
- Fischer J, Ganellin CR (2006). Analogue-based Drug Discovery. John Wiley & Sons. p. 494. ISBN 9783527607495.
- Bui T, Preuss CV (2020). Cephalosporins. StatPearls. StatPearls Publishing. PMID 31855361. Retrieved 2020-04-23.
- Perry CM, Brogden RN (July 1996). "Cefuroxime axetil. A review of its antibacterial activity, pharmacokinetic properties and therapeutic efficacy". Drugs. 52 (1): 125–58. doi:10.2165/00003495-199652010-00009. PMID 8799689. S2CID 46985101.
- GlaxoSmithKline (2015). "Ceftin (cefuroxime axetil)" (PDF). FDA. Retrieved 22 April 2020.
- Zinnat SUMMARY OF PRODUCT CHARACTERISTICS - GSKPro for Healthcare Professionals
- "Our history - About GSK". GlaxoSmithKline. Archived from the original on 2011-05-14.
- "Cefuroxime Axetil Monograph for Professionals". Drugs.com. Retrieved 2018-04-22.
- "Brands". Gsksource.com. 2018-03-22. Archived from the original on 2016-03-20. Retrieved 2018-04-22.
- "Our products". GlaxoSmithKline.